Bio-Techne said consolidated net sales for fiscal 2025 increased 5% compared to the prior year to $1.2 billion, with organic growth of 5%. Consolidated net earnings decreased 56%, and the company cited the impact of a non-recurring loss on an arbitration award, impairment of assets held-for-sale, and restructuring and restructuring-related charges.

10-KAnnual reportFiled Aug 22, 2025Period of report Jun 30, 2025Summary published (UTC) Oct 11, 2026

Key points

AI summary

Bio-Techne said consolidated net sales for fiscal 2025 increased 5% compared to the prior year to $1.2 billion, with organic growth of 5%. Consolidated net earnings decreased 56%, and the company cited the impact of a non-recurring loss on an arbitration award, impairment of assets held-for-sale, and restructuring and restructuring-related charges.
Bio-Techne said consolidated gross margins were 64.8% in fiscal 2025, 66.4% in fiscal 2024, and 67.7% in fiscal 2023. Adjusted gross margins were 70.4%, 71.0%, and 71.7%, respectively, and the company cited the impact of reinstatement of incentive accruals and product mix in fiscal 2025.
Bio-Techne said it generated cash from operations of $287.6 million in fiscal 2025 and $299.0 million in fiscal 2024. In the same period, the company repurchased $275.7 million in shares and paid $50.4 million in cash dividends.
The company said it must acquire the remaining 80.1% of Wilson Wolf by December 31, 2027, with the timing accelerated if certain financial milestones are met. The second option payment of approximately $1 billion plus potential contingent consideration is expected to occur between fiscal 2026 and fiscal 2028.

Key figures

Fiscal year ended June 30, 2025

Revenue: $1.2B
Operating income: $102M
Net income: $73M
EPS: $0.46
Gross profit: $790M
Operating cash flow: $288M

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Annual net sales up 5%, net earnings down 56%

Bio-Techne said consolidated net sales for fiscal 2025 increased 5% compared to the prior year to $1.2 billion, with organic growth of 5%. Consolidated net earnings decreased 56%, and the company cited the impact of a non-recurring loss on an arbitration award, impairment of assets held-for-sale, and restructuring and restructuring-related charges.

Source · Based on the MD&A text of the filing

Gross margin 64.8%, adjusted 70.4%

Bio-Techne said consolidated gross margins were 64.8% in fiscal 2025, 66.4% in fiscal 2024, and 67.7% in fiscal 2023. Adjusted gross margins were 70.4%, 71.0%, and 71.7%, respectively, and the company cited the impact of reinstatement of incentive accruals and product mix in fiscal 2025.

Source · Based on the MD&A text of the filing

Operating cash $287.6 million, share repurchases $275.7 million

Bio-Techne said it generated cash from operations of $287.6 million in fiscal 2025 and $299.0 million in fiscal 2024. In the same period, the company repurchased $275.7 million in shares and paid $50.4 million in cash dividends.

Source · Based on the MD&A text of the filing

Wilson Wolf remaining interest acquisition commitment approximately $1 billion

The company said it must acquire the remaining 80.1% of Wilson Wolf by December 31, 2027, with the timing accelerated if certain financial milestones are met. The second option payment of approximately $1 billion plus potential contingent consideration is expected to occur between fiscal 2026 and fiscal 2028.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.